Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 9/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9902165 | 0.89 | KCNA5 (0.58) | KCNA5KCNH2 | |
| SCHEMBL9901968 | 0.89 | KCNA5 (0.58) | KCNA5KCNH2 | |
| SCHEMBL1242047 | 0.81 | LMNA (0.46) | POLBKCNA5EPHX2 | |
| SCHEMBL1242102 | 0.81 | RAB9A (0.41) | POLBKCNA5EPHX2KCNH2KDM4E | |
| SCHEMBL1243103 | 0.81 | ADAMTS5 (0.41) | POLBKCNA5EPHX2CYP11B1CYP11B2 | |
| SCHEMBL1240787 | 0.80 | KCNA5 (0.53) | KCNA5KCNH2 | |
| SCHEMBL1240785 | 0.80 | KCNA5 (0.53) | KCNA5KCNH2 | |
| SCHEMBL4577826 | 0.80 | KCNA5 (0.53) | KCNA5KCNH2 | |
| SCHEMBL1240499 | 0.79 | ADORA3 (0.48) | — | |
| SCHEMBL1242256 | 0.79 | TDP1 (0.54) | POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781635-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | POLB 4819/4885KCNA5 11/4885EPHX2 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.